Furiex Makes Inroads In Tough-To-Treat IBS-d With Positive Phase III Eluxadoline Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Eluxadoline met endpoints in two Phase III studies, positioning the drug for submission in a sparsely served therapeutic area, with only one FDA-approved drug and millions of patients in the U.S. and EU. Mild pancreatitis was reported in a handful of patients, but is manageable, company says.